Positioned to transform the HBV treatment landscape and address the HBV global market opportunity
Portfolio of assets combining multiple technologies aimed at curing HBV
Proven scientific leadership in antiviral and RNAi drug discovery and development
Arbutus Biopharma Corporation (NASDAQ: ABUS) is a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of assets with different modes of action to provide a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple product candidates with distinct mechanisms of action that suppress viral replication, reduce surface antigen and reawaken the immune system. Arbutus believes this three-prong approach is key to transforming the treatment and developing a potential cure for chronic HBV infection. Arbutus’ HBV product pipeline includes RNA interference (RNAi) therapeutics, oral capsid inhibitors, oral compounds that inhibit PD-L1 and oral HBV RNA destabilizers. In addition, Arbutus has an ongoing drug discovery and development program directed to identifying orally active agents for treating coronaviruses (including COVID-19).
Arbutus has a very broad HBV product pipeline of assets to reduce surface antigen, suppress viral replication, and boost the immune system, which include: RNAi therapeutic, Capsid Inhibitor, oral PD-L1 inhibitor, oral HBV RNA Destabilizers and additional coronavirus pre-clinical assets.
